ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Enhancement of antioxidant and cytotoxicity by nanoliposome formulation of pentagamavunon-6 in breast cancer cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains highly prevalent due to its complex etiology. Curcumin, a natural compound with therapeutic potential, faces physicochemical limitations, leading to the development of its synthetic analog, pentagamavunon-6 (PGV-6). However, PGV-6's low aqueous solubility limits its efficacy, necessitating nanoliposome-based encapsulation to enhance its effectiveness. This study is aimed at synthesizing, characterizing, and evaluating the antioxidant and anticancer properties of PGV-6-loaded nanoliposome (NLP). The NLPs were fabricated using the thin film hydration technique which composed of LPC, cholesterol, Tween-80, and PGV-6 (28:4.3:7.8:1). The particle characterization was conducted by measuring particle size, polydispersity index (PDI), and zeta potential using PSA and observing their morphology using SEM and HR-TEM. Antioxidant activity was assessed using ABTS assay, while anticancer effects were evaluated through cytotoxicity, apoptosis, lysosomal uptake, ROS generation, and cell cycle assays on MCF-7 breast cancer cells. The NLP formed spherical nanoparticles with a mean particle size of 127.7 ± 1.75 nm, PDI of 0.2 ± 0.03, and zeta potential of - 7.8 ± 0.64 mV. The NLP enhanced the antioxidant activity of PGV-6 by 15.4-fold (IC
Indexed as
Identifiers
40848136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.